Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | F Hoffmann La Roche AG | 151 |
| 2 | Pfizer Inc | 123 |
| 3 | Amgen Inc | 87 |
| 4 | Pfizer Corp SRL | 84 |
| 5 | Boehringer Ingelheim Pharmaceuticals Inc | 65 |
| 6 | Takeda Pharmaceutical Co Ltd | 59 |
| 7 | Pfizer Corp Belgium | 49 |
| 8 | Eli Lilly and Co | 45 |
| 9 | Abbott Laboratories | 42 |
| 10 | AstraZeneca AB | 40 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | C07D | Heterocyclic compounds | 3,258 |
| 2 | A61P | Therapeutic activity (drug indications) | 2,548 |
| 3 | A61K | Medicinal preparations | 1,264 |
| 4 | C07C | Acyclic and carbocyclic compounds | 484 |
| 5 | A01N | Preservation of bodies; biocides; pest repellents | 262 |
| 6 | Y02A | Climate change adaptation | 158 |
| 7 | C07F | Organometallic compounds | 151 |
| 8 | C07B | General methods of organic chemistry | 109 |
| 9 | Y02P | Climate change mitigation: production | 98 |
| 10 | C07K | Peptides | 88 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionMost-cited patents
Patents ranked by forward citations reveal the foundational inventions the field continues to build on.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| Preparation method of 2-chloronicotinic acid | 2008 | Zhejiang Medicine Co Ltd | 23 |
| PREPARATION OF 2-CHLORONICOTINIC ACID | 1984 | YUKI GOSEI YAKUHIN KOGYO KK | 10 |
| Nitrilase mutant and application thereof in catalytic synthesis of 2-chloronicotinic acid | 2020 | Zhejiang University of Technology | 9 |
| Process for the production of pure white 2-chloronicotinic acid | 1979 | Lonza AG | 8 |
| Synthesis method of 2-chloronicotinic acid and derivative thereof | 2013 | Zhejiang University of Technology | 7 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Bruce S. Edwards | University of New Mexico | 3 |
| 2 | Islam Ullah Khan | Government College University, Lahore | 3 |
| 3 | Larry A. Sklar | University of New Mexico | 3 |
| 4 | Matthew Saunders | University of New Mexico | 3 |
| 5 | Misbahul Ain Khan | Islamia University of Bahawalpur | 3 |
| 6 | Muhammad Nadeem Arshad | Government College University, Lahore | 3 |
| 7 | Muhammad Naeem Khan | Islamia University of Bahawalpur | 3 |
| 8 | Steven W. Graves | Los Alamos National Laboratory | 3 |
| 9 | Anton Simeonov | National Center for Advancing Translational Sciences | 2 |
| 10 | Muhammad Nawaz Tahir | University of Sargodha | 2 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| 2-Bromopyridine-3-carboxylic acid | 2010 | 84 | Metal complexes synthesis and properties |
| Host intra-clutch variation, cuckoo egg matching and egg rejection by great reed warblers | 2007 | 83 | Avian ecology and behavior |
| A pioneer study on the anti-ulcer activities of copper nicotinate complex [CuCl (HNA)2] in experimental gastric ulcer induced by aspirin-pyloris ligation model (Shay model) | 2008 | 33 | Helicobacter pylori-related gastroenterology studies |
| Characterization of a newly isolated strain Rhodococcus erythropolis ZJB-09149 transforming 2-chloro-3-cyanopyridine to 2-chloronicotinic acid | 2011 | 19 | Enzyme Catalysis and Immobilization |
| 5<i>H</i>-1-Benzothiopyrano[2,3-<i>b</i>]pyridin-5-one | 2008 | 6 | Synthesis and biological activity |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular formula and weight of 2-Chloronicotinic acid?
Which pharmaceutical companies hold the most patents involving this compound?
What are the main patent applications for 2-Chloronicotinic acid synthesis?
What research topics are associated with published papers on this compound?
How has patenting activity for 2-Chloronicotinic acid changed in recent years?